Calliditas Therapeutics AB American Depositary Shares

Calliditas Therapeutics announced that it will delist its common shares from Nasdaq Stockholm and its American Depositary Shares from the Nasdaq Global Select Market, following Asahi Kasei's acquisition of over 90% of the company's shares.

Related tickers: CALT, AHKSY.

In the last three months, 5 analysts have published ratings on Calliditas Therapeutics (NASDAQ:CALT), offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 3 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.4, along with a high estimate of $45.00 and a low estimate of $39.00. Highlighting a 25.64% decrease, the current average has fallen from the previous average price target of $54.33. Analyzing Analyst Ratings: A Detailed Breakdown A clear picture of Calliditas Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Yigal Nochomovitz Citigroup Announces Neutral $39.00 - Maury Raycroft Jefferies Lowers Hold $39.00 $58.00 Annabel Samimy Stifel Lowers Hold $40.00 $55.00 Arthur He HC Wainwright & Co. Announces Neutral $39.00 - Arthur He HC Wainwright & Co. Lowers Buy $45.00 $50.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' ...Full story available on Benzinga.com

Related tickers: CALT.